Crescendo Biologics: Aid for late-stage development

Cambridge-based immuno-oncology developer Crescendo Biologics had named Philip Bland-Ward as its Chief Scientific Officer. He joins Crescendo from Kymab where he was responsible for leading its most advanced development programme.

Previously, Bland-Ward held senior positions at Cambridge Antibody Technology and PanGenetics and was CSO at Navion, as well as a co-founder of Nascient. He holds a BPharm degree in pharmacy and a PhD in pharmacology, both from Kings College London, and started his career working on pain and migraine research at the Glaxo Institute of Applied Pharmacology and then at GlaxoWellcome.